PhRMA lobby spend grows to $15.5M in the first half of 2018

Boardroom
PhRMA's lobbying included issues relating to generics and patents, plus much more. (Pixabay)

As the pharmaceutical industry faces potential pricing reform and continued criticism from patient advocates and members of Congress, the industry's top trade group spent $15.5 million lobbying in the first half, an 11.5% increase compared with the same period last year.

PhRMA lobbied both chambers of Congress, plus federal agencies including the HHS, FDA, CMS and more, according to the documents. It worked on issues relating to patents, inter partes reviews, opioids, drug pricing, generics and much more, spending $1.6 million more than the same period last year, according to filings. In all, it spent $15.5 million in the first six months of 2018.

A PhRMA spokesperson said she could not discuss lobbying strategy but that issues being discussed have significant implications for patients. "We think it is vital to be engaged and a big part of what we are focused on is coming to the table with solutions to address improve patient affordability and access."

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

Engaged it is. Last year in the first half, PhRMA spent $13.9 million in lobbying expenses. By the time 2017 was over, the group had boosted its spend by 30% over 2016 levels to a total of more than $25 million.

RELATED: Under fire for pricing and more, PhRMA boosts lobbying spend 30% in 2017

The spending comes as the industry faces close scrutiny from President Donald Trump and a range of critics over its pricing strategies. Early last year, then-president elect Trump said the industry was "getting away with murder." He also blasted the industry's lobbying power.

Then, early this month, the president took Pfizer to task over its second round of price hikes for the year. The drug giant ended up reversing those hikes in a move that sparked a new round of intense discussion over pricing. Pfizer have since pledged to pause price hikes for the year, pledges that critics say will provide little relief for consumers or little pain for drugmakers.

In May, the Trump administration unveiled its drug pricing blueprint, a development many industry watchers actually saw as a positive for pharma companies. The plan seeks to boost competition and price negotiations, plus take on industry tactics that have reduced competition. Wells Fargo analyst David Maris wrote after the announcement that the administration is "actually trying to address some of the root causes of price inflation and lack of affordability."

But one consultant told FiercePharma afterward it looked like "business as usual" for industry players in the short term. 

Suggested Articles

One year after its landmark Reduce-It CV outcomes trial, Amarin has new data showing its Vascepa may help halt the progress of arterial plaque.

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

In its quest to become the dominant SGLT2 diabetes med for heart failure, Jardiance is touting DPP-4 inhibitor-topping data to support its case.